Molecular Aspects of Tumor Microenvironment of Acute Myeloid Leukemia

Dear Colleagues,

We are pleased to announce the upcoming Special Issue of Cancers, entitled “Molecular Aspects of Tumor Microenvironment of Acute Myeloid Leukemia (AML)”.

Recent advances have introduced new therapies for the treatment of AML, yet they remain highly toxic and the disease is only curable in a minority of patients. A better understanding of how AML develops from normal hematopoietic stem and progenitor cells and becomes resistant to chemotherapy and targeted agents is needed. The hematopoietic microenvironment was introduced as concept in 1978 and now includes multiple defined niches including stromal, endosteal, vascular, adipose, nervous and other cell types. The AML tumor microenvironment is its pathological counterpart; evidence shows that malignant and pre-malignant HSCs can remodel their surroundings, resulting in the selection and promotion of abnormal clones. The tumor microenvironment may generate altered metabolic states in AML cells, promote immune dysfunction, and provide elevated concentrations of factors that support AML cell growth and induce resistance to chemotherapy and targeted agents. The role of the microenvironment in the evolution and treatment of AML are active areas of investigation.

In this Special Issue, original research articles and reviews on the molecular aspects of the AML tumor microenvironment are welcome. Research may touch, but is not limited to, the following areas: inflammation, aging, cytokine/chemokine biology, growth factors and cell signal transduction, cell trafficking, clonal evolution, metabolism, translational therapeutics, and drug resistance. Articles should examine the role of extrinsic cell factors in AML biology; priority will be given to in vivo studies.
       
We look forward to receiving your contributions.

Dr. Bradley W. Blaser
Dr. Vera Binder
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• AML
• microenvironment
• resistance
• niche
• targeted chemotherapy
• growth factor
• extrinsic
• metabolism
• inflammation